Home » Pneumococcal Vaccines Market

Pneumococcal Vaccines Market By Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine), By Product Type (10-Valent PCV, 13-valent PCV, 23-valent PPSV) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Price: $4999

Published: | Report ID: 9696 | Report Format : PDF

Industry Outlook

The global pneumococcal vaccines market held US$ 7,108.7 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 5.1% during the forecast period from 2018 to 2026. Pneumococcal diseases are one of the leading cause of serious illness globally resulting in high number of hospitalization every year. Diseases caused by pneumococcus bacteria include pneumonia, otitis media, sinus, meningitis and sepsis. According to National Foundation of Infectious Diseases (NFID), more than one million adults in the U.S. suffer from pneumococcal pneumonia every year and close to half a million people hospitalizations occur annually in the United States. The burden of pneumococcal diseases is higher in children below 5 years old and adults above 65 years. Developing countries are the most affected by pneumococcal diseases, for instance, India holds the highest number of global pneumonia deaths, accounting for 20 percent of worldwide pneumonia deaths in children below the age of 5. However, constant initiatives by government across the world and private health organizations there has been significant reduction in number deaths occurring, especially in the developing countries.

The market players operating in the market are focusing on low income countries and developing countries by investing and partnering with local players to maintain the supply of vaccines in the region. North America held the largest share in the global pneumococcal vaccines market owing to the domicile of two major pneumococcal vaccines producers (Pfizer, Inc. and Merck & Co., Inc.) in the region. Pneumococcal conjugate vaccines produced by these pharma giants is part of the routine vaccine program in the U.S. and Canada. Asia Pacific and Latin America are projected to witness significant growth during the forecast period owing to high burden of pneumococcal diseases in the region and supportive government policies rendering market growth.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Market Synopsis

13-valent PCV Set to Drive the Market of Pneumococcal Vaccines Market

In 2017, 13-valent PCV vaccine held the largest share in the global pneumococcal vaccines market. PVC13 offers a significant benefit for preventing pneumonia and invasive diseases caused by Streptococcus pneumonia in adults and children. The Centers for Disease Control and Prevention (CDC) PCV13 vaccines for children below 2 and adults above 65 years of age. Moreover, it is now recommended that adults above 65 and older to get both PCV13 and PPSV23 vaccine for better immunogenicity against various serotypes of pneumococcus. Moreover, Pfizer’s 20-valent PCV and Merck’s 15-valent PCV are in the late stage of the clinical trials and expected to enter the market during the forecast period, which will further provide thrust to pneumococcal market.

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Report Scope by Segments

Pneumococcal Vaccines market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on vaccine type, product type, and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation  By Vaccine Type (2016–2026; US$ Mn)
• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine
 By Product Type (2016 – 2026; Mn)
• 10-valent PCV
• 13-valent PCV
• 23-valent PPSV
• Pipeline Analysis
• 15-valent PCV
• 20-valent PCV
 Geography Segment (2016–2026; US$ Mn)
• North America (U.S. and Canada)
• Europe (U.K., Germany, and Rest of Europe)
• Asia Pacific (Japan, China, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of Middle East and Africa)

Market is studied in order to understand the current dynamics and future trends in the global pneumococcal vaccines market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in pneumococcal vaccines market include Pfizer, Inc., Merck & Co., Inc. and GlaxoSmithKline plc.

Key questions answered in this report

  • How the global pneumococcal vaccines market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the pneumococcal vaccines market and valuable opportunities for key players?
  • Who are the leading players in the global pneumococcal vaccines market?
  • Which is the leading/and fastest region in the global pneumococcal vaccines market?
  • What are drivers and restrains governing the global pneumococcal vaccines market?
  • What is the epidemiology of pneumococcal diseases worldwide?
  • How is the pipeline of the pneumococcal vaccines?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global PV Market Portraiture
2.2. Global PV Market, by Vaccine Type, 2017 (US$ Mn)
2.3. Global PV Market, by Product Type, 2017 (US$ Mn)
2.4. Global PV Market, by Geography, 2017 (US$ Mn)

Chapter 3. Pneumococcal Vaccines (PV) Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global PV Market, by Key Players, 2017

Chapter 4. Global Pneumococcal Vaccines (PV) Market, by Vaccine Type, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Pneumococcal Conjugate Vaccine
4.3. Pneumococcal Polysaccharide Vaccine

Chapter 5. Global Pneumococcal Vaccines (PV) Market, by Product Type, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. 10-valent PCV
5.3. 13-valent PCV
5.4. 23-valent PPSV
5.5. Pipeline Analysis
5.5.1. Phase III Analysis
5.5.1.1. 15-valent PCV
5.5.1.2. 20-valent PCV
5.5.2. Tabular Representation of Phase I and Phase II Vaccines

Chapter 6. Global Pneumococcal Vaccines (PV) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. North America PV Market Analysis, 2016 – 2026
6.1.1. North America PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
6.1.2. North America PV Market, by Product Type, 2016 – 2026 (US$ Mn)
6.1.3. North America PV Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe PV Market Analysis, 2016 – 2026
6.2.1. Europe PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
6.2.2. Europe PV Market, by Product Type, 2016 – 2026 (US$ Mn)
6.2.3. Europe PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific PV Market Analysis, 2016 – 2026
6.3.1. Asia Pacific PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
6.3.2. Asia Pacific PV Market, by Product Type, 2016 – 2026 (US$ Mn)
6.3.3. Asia Pacific PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America PV Market Analysis, 2016 – 2026
6.4.1. Latin America PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
6.4.2. Latin America PV Market, by Product Type, 2016 – 2026 (US$ Mn)
6.4.3. Latin America PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa PV Market, 2016 – 2026
6.5.1. Middle East & Africa PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
6.5.2. Middle East & Africa PV Market, by Product Type, 2016 – 2026 (US$ Mn)
6.5.3. Middle East & Africa PV Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. Pfizer, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. GlaxoSmithKline PLC
7.3. Merck & Co., Inc.

List of Figures

FIG 1. Pneumococcal Vaccines (PV) Market: Research Methodology
FIG 2. PV Market Segmentation
FIG 3. Global PV Market, by Vaccine Type, 2017 (US$ Mn)
FIG 4. Global PV Market, by Product Type, 2017 (US$ Mn)
FIG 5. Global PV Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global PV Market, by Key Players, 2017
FIG 8. Global Pneumococcal Conjugate Vaccines (PCV) Market, 2016-2026 (US$ Mn)
FIG 9. Global Pneumococcal Polysaccharide Vaccines (PPSV) Market, 2016-2026(US$ Mn)
FIG 10. Global 10-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 11. Global 13-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 12. Global 23-valent PPSV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 13. Global 15-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 14. Global 20-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 15. U.S. PV Market, 2016-2026 (US$ Mn)
FIG 16. Canada PV Market, 2016-2026 (US$ Mn)
FIG 17. U.K. PV Market, 2016-2026 (US$ Mn)
FIG 18. Germany PV Market, 2016-2026 (US$ Mn)
FIG 19. Rest of Europe PV Market, 2016-2026 (US$ Mn)
FIG 20. China PV Market, 2016-2026 (US$ Mn)
FIG 21. Japan PV Market, 2016-2026 (US$ Mn)
FIG 22. Rest of Asia Pacific PV Market, 2016-2026 (US$ Mn)
FIG 23. Brazil PV Market, 2016-2026 (US$ Mn)
FIG 24. Mexico PV Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Latin America PV Market, 2016-2026 (US$ Mn)
FIG 26. GCC PV Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Middle East & Africa PV Market, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Pneumococcal Vaccines (PV) Market Portraiture
TABLE 2 Global Pneumococcal Vaccines Discovery Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 4 Pipeline Analysis: Phase I & II Vaccines
TABLE 5 Global PV Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 7 North America PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 8 North America PV Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 9 Europe PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 10 Europe PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 11 Europe PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 17 Latin America PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East & Africa PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East & Africa PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East & Africa PV Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 21 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Merck & Co., Inc..: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions

What is the size of Pneumococcal Vaccines Market?

The market for Pneumococcal Vaccines is expected to reach US$ 6.56 Bn in 2028.

What is the Pneumococcal Vaccines Market CAGR?

The Pneumococcal Vaccines market is expected to see significant CAGR growth over the coming years, at 15.0%.

What is the Forecast period considered for Pneumococcal Vaccines Market?

The report is forecasted from 2019-2027.

What is the base year considered for Pneumococcal Vaccines Market?

The base year of this report is 2021.

Who are the major players in this market?

Capgemini S.A., EMC Corporation, Hitachi, Ltd., Hewlett-Packard, IBM Corporation, Newgen Software, Inc., Cisco Systems, Inc., SAP SE, SAS Institute, Tata Consultancy Services Ltd. are some of the major players in the global market.

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Basal Cell Carcinoma (BCC) Treatment Market

Published:
Report ID: 32698

Paroxysmal Nocturnal Hemoglobinuria Market

Published:
Report ID: 8654

Reversible Airway Diseases Treatment Market

Published:
Report ID: 32531

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN